Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV002506738 | SCV002815770 | uncertain significance | Short-rib thoracic dysplasia 10 with or without polydactyly; Retinitis pigmentosa 71; Bardet-Biedl syndrome 20 | 2024-05-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002539697 | SCV003729100 | uncertain significance | Inborn genetic diseases | 2021-07-14 | criteria provided, single submitter | clinical testing | The c.3713A>C (p.E1238A) alteration is located in exon 34 (coding exon 34) of the IFT172 gene. This alteration results from a A to C substitution at nucleotide position 3713, causing the glutamic acid (E) at amino acid position 1238 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Gene |
RCV001699869 | SCV005688402 | uncertain significance | not provided | 2024-08-02 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Clinical Genetics, |
RCV001699869 | SCV001924595 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV001699869 | SCV001975160 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Institute of Human Genetics, |
RCV004815594 | SCV005071279 | uncertain significance | Retinal dystrophy | 2020-01-01 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004738363 | SCV005346456 | uncertain significance | IFT172-related disorder | 2024-08-06 | no assertion criteria provided | clinical testing | The IFT172 c.3713A>C variant is predicted to result in the amino acid substitution p.Glu1238Ala. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0094% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |